Curis Inc. Stock
Curis Inc. Stock
Pros and Cons of Curis Inc. in the next few years
Pros
Cons
Performance of Curis Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Curis Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 5.440% | -0.366% | -11.361% | 47.951% | 3.668% | -1.770% | - |
| Salarius Pharmaceuticals Inc. | -2.830% | -3.738% | -2.830% | -71.389% | -25.766% | -98.474% | -99.994% |
| Brainstorm Cell | 6.550% | -29.447% | -33.143% | -87.283% | 51.293% | -87.897% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Curis Inc. (CRIS) operates in the highly competitive and rapidly evolving biotechnology and medical research industry. On the surface, the company's financials present a mixed picture, with some positive aspects, as well as potential areas of concern. Overall, the financial state of Curis warrants a deeper analysis to identify the positive and negative aspects that may impact the company's future prospects.
Growth in total revenue: Curis has experienced an increase in its total revenue from $10.83 million in 2020 to $10.16 million in 2021 and $10.89 million in 2022. This indicates that the company is successfully generating income from its operations, which is a positive sign for investors.
Short-term investments: Curis has maintained substantial short-term investments in its balance sheet. In 2022, these investments stood at $65.97 million, providing the company with an opportunity to generate additional income and to have a cushion to meet its short-term obligations.
Comments